메뉴 건너뛰기




Volumn 7, Issue 13, 2008, Pages 752-757

Can Intermittent Hormone Therapy Fulfil its Promise?

Author keywords

Intermittent hormone therapy; Prostate cancer; Quality of life; Review article; Side effects

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

EID: 54549085353     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2008.09.002     Document Type: Review
Times cited : (12)

References (23)
  • 1
    • 36448936367 scopus 로고    scopus 로고
    • EAU guidelines on prostate cancer
    • Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
    • (2008) Eur Urol , vol.53 , pp. 68-80
    • Heidenreich, A.1    Aus, G.2    Bolla, M.3
  • 2
    • 26444462106 scopus 로고    scopus 로고
    • Optimising hormone therapy in advanced disease
    • Boccon-Gibod L. Optimising hormone therapy in advanced disease. Eur Urol Suppl 4 8 (2005) 21-29
    • (2005) Eur Urol Suppl , vol.4 , Issue.8 , pp. 21-29
    • Boccon-Gibod, L.1
  • 3
    • 33845645525 scopus 로고    scopus 로고
    • The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight
    • Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int 99 Suppl 1 (2007) 19-22
    • (2007) BJU Int , vol.99 , Issue.SUPPL. 1 , pp. 19-22
    • Tunn, U.1
  • 4
    • 33745172826 scopus 로고    scopus 로고
    • Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer
    • Mottet N., Prayer-Galetti T., Hammerer P., Kattan M.W., and Tunn U. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int 98 (2006) 20-27
    • (2006) BJU Int , vol.98 , pp. 20-27
    • Mottet, N.1    Prayer-Galetti, T.2    Hammerer, P.3    Kattan, M.W.4    Tunn, U.5
  • 5
    • 0037299782 scopus 로고    scopus 로고
    • Side effects of androgen deprivation therapy: monitoring and minimizing toxicity
    • Higano C.S. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 61 Suppl 1 (2003) 32-38
    • (2003) Urology , vol.61 , Issue.SUPPL. 1 , pp. 32-38
    • Higano, C.S.1
  • 6
    • 33749058933 scopus 로고    scopus 로고
    • Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
    • Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
    • (2006) J Clin Oncol , vol.24 , pp. 4448-4456
    • Keating, N.L.1    O'Malley, A.J.2    Smith, M.R.3
  • 7
    • 34347271955 scopus 로고    scopus 로고
    • Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions
    • D'Amico A.V., Denham J.W., Crook J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25 (2007) 2420-2425
    • (2007) J Clin Oncol , vol.25 , pp. 2420-2425
    • D'Amico, A.V.1    Denham, J.W.2    Crook, J.3
  • 8
    • 34648828214 scopus 로고    scopus 로고
    • Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
    • Saigal C.S., Gore J.L., Krupski T.L., Hanley J., Schonlau M., and Litwin M.S. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110 (2007) 1493-1500
    • (2007) Cancer , vol.110 , pp. 1493-1500
    • Saigal, C.S.1    Gore, J.L.2    Krupski, T.L.3    Hanley, J.4    Schonlau, M.5    Litwin, M.S.6
  • 10
    • 0028808382 scopus 로고
    • The final analysis of the EORTC Genito-Urinary Tract Cancer Co-operative Group Phase III clinical trial (Protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate, and low dose stilboestrol in the management of metastatic carcinoma of the prostate
    • Robinson M.R., Smith P.H., Richards B., Newling D.W., de Pauw M., and Sylvester R. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-operative Group Phase III clinical trial (Protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate, and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 28 (1995) 273-283
    • (1995) Eur Urol , vol.28 , pp. 273-283
    • Robinson, M.R.1    Smith, P.H.2    Richards, B.3    Newling, D.W.4    de Pauw, M.5    Sylvester, R.6
  • 11
    • 0027416692 scopus 로고
    • Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen
    • Akakura K., Bruchovsky N., Goldenberg S.L., Rennie P.S., Buckley A.R., and Sullivan L.D. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 71 (1993) 2782-2790
    • (1993) Cancer , vol.71 , pp. 2782-2790
    • Akakura, K.1    Bruchovsky, N.2    Goldenberg, S.L.3    Rennie, P.S.4    Buckley, A.R.5    Sullivan, L.D.6
  • 12
    • 0025246690 scopus 로고
    • Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma
    • Bruchovsky N., Rennie P.S., Coldman A.J., Goldenberg S.L., To M., and Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50 (1990) 2275-2282
    • (1990) Cancer Res , vol.50 , pp. 2275-2282
    • Bruchovsky, N.1    Rennie, P.S.2    Coldman, A.J.3    Goldenberg, S.L.4    To, M.5    Lawson, D.6
  • 13
    • 0028245279 scopus 로고
    • Effect of tumour progression on the androgenic regulation of the androgen receptor. TRPM-2 and YPT1 genes in the Shionogi carcinoma
    • Rennie P.S., Bruchovsky N., Akakura K., et al. Effect of tumour progression on the androgenic regulation of the androgen receptor. TRPM-2 and YPT1 genes in the Shionogi carcinoma. J Steroid Biochem Mol Biol 50 (1994) 31-40
    • (1994) J Steroid Biochem Mol Biol , vol.50 , pp. 31-40
    • Rennie, P.S.1    Bruchovsky, N.2    Akakura, K.3
  • 14
    • 0027239899 scopus 로고
    • Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol
    • Bruchovsky N., Goldenberg S.L., Akakura K., and Rennie P.S. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol. Cancer 72 (1993) 1685-1691
    • (1993) Cancer , vol.72 , pp. 1685-1691
    • Bruchovsky, N.1    Goldenberg, S.L.2    Akakura, K.3    Rennie, P.S.4
  • 15
    • 0029656221 scopus 로고    scopus 로고
    • Biochemical and pathological effects of 8 mo of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer
    • Gleave M.E., Goldenberg S.L., Jones E.C., Bruchovsky N., and Sullivan L.D. Biochemical and pathological effects of 8 mo of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 155 (1996) 213-219
    • (1996) J Urol , vol.155 , pp. 213-219
    • Gleave, M.E.1    Goldenberg, S.L.2    Jones, E.C.3    Bruchovsky, N.4    Sullivan, L.D.5
  • 16
    • 33645341444 scopus 로고    scopus 로고
    • Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model
    • Eggener S.E., Stern J.A., Jain P.M., et al. Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate 66 (2006) 495-502
    • (2006) Prostate , vol.66 , pp. 495-502
    • Eggener, S.E.1    Stern, J.A.2    Jain, P.M.3
  • 17
    • 34247111243 scopus 로고    scopus 로고
    • International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients
    • Shaw G.L., Wilson P., Cuzick J., et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int 99 (2007) 1056-1065
    • (2007) BJU Int , vol.99 , pp. 1056-1065
    • Shaw, G.L.1    Wilson, P.2    Cuzick, J.3
  • 18
    • 33748465540 scopus 로고    scopus 로고
    • Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)
    • Hussain M., Tangen C.M., Higano C., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24 (2006) 3984-3990
    • (2006) J Clin Oncol , vol.24 , pp. 3984-3990
    • Hussain, M.1    Tangen, C.M.2    Higano, C.3
  • 19
    • 34948835932 scopus 로고    scopus 로고
    • Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer
    • abstract 5015
    • Miller K., Steiner U., Lingnau A., et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol 25 (2007) 2385 abstract 5015
    • (2007) J Clin Oncol , vol.25 , pp. 2385
    • Miller, K.1    Steiner, U.2    Lingnau, A.3
  • 20
    • 33845358538 scopus 로고    scopus 로고
    • Phase III intermittent MAB vs continuous MAB
    • abstract 4513
    • Calais Da Silva F.M., Calais Da Silva F., Bono A., et al. Phase III intermittent MAB vs continuous MAB. J Clin Oncol 24 (2006) 220 abstract 4513
    • (2006) J Clin Oncol , vol.24 , pp. 220
    • Calais Da Silva, F.M.1    Calais Da Silva, F.2    Bono, A.3
  • 21
    • 48849104783 scopus 로고    scopus 로고
    • Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation
    • Salonen A.J., Viitanen J., Lundstedt S., la-Opas M., Taari K., and Tammela T.L. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. J Urol 180 (2008) 915-919
    • (2008) J Urol , vol.180 , pp. 915-919
    • Salonen, A.J.1    Viitanen, J.2    Lundstedt, S.3    la-Opas, M.4    Taari, K.5    Tammela, T.L.6
  • 22
    • 3442876782 scopus 로고    scopus 로고
    • Intermittent is as effective as continuous androgen deprivation in patients with PSA relapse after radical prostatectomy (RP)
    • abstract 1458
    • Tunn U., Kurek R., Kienle E., and Maubach L. Intermittent is as effective as continuous androgen deprivation in patients with PSA relapse after radical prostatectomy (RP). J Urol 171 (2004) 384 abstract 1458
    • (2004) J Urol , vol.171 , pp. 384
    • Tunn, U.1    Kurek, R.2    Kienle, E.3    Maubach, L.4
  • 23
    • 54549109116 scopus 로고    scopus 로고
    • Intermittent androgen deprivation in patients with PSA relapse after radical prostatectomy-final results of a European randomized prospective phase-III clinical trial AUO study AP 06/95, EC 507
    • abstract 600
    • Tunn U.W., Canepa G., Hillger H., and Fuchs W. Intermittent androgen deprivation in patients with PSA relapse after radical prostatectomy-final results of a European randomized prospective phase-III clinical trial AUO study AP 06/95, EC 507. J Urol 177 (2007) 201 abstract 600
    • (2007) J Urol , vol.177 , pp. 201
    • Tunn, U.W.1    Canepa, G.2    Hillger, H.3    Fuchs, W.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.